Thalidomide (DrugBank: Thalidomide)
20 diseases| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 2 | 筋萎縮性側索硬化症 | 2 |
| 16 | クロウ・深瀬症候群 | 3 |
| 20 | 副腎白質ジストロフィー | 1 |
| 28 | 全身性アミロイドーシス | 8 |
| 49 | 全身性エリテマトーデス | 1 |
| 51 | 全身性強皮症 | 1 |
| 53 | シェーグレン症候群 | 1 |
| 56 | ベーチェット病 | 1 |
| 65 | 原発性免疫不全症候群 | 3 |
| 84 | サルコイドーシス | 1 |
| 85 | 特発性間質性肺炎 | 3 |
| 94 | 原発性硬化性胆管炎 | 1 |
| 96 | クローン病 | 8 |
| 97 | 潰瘍性大腸炎 | 2 |
| 227 | オスラー病 | 3 |
| 271 | 強直性脊椎炎 | 4 |
| 280 | 巨大動静脈奇形（頚部顔面又は四肢病変） | 2 |
| 298 | 遺伝性膵炎 | 1 |
| 300 | IgG4関連疾患 | 1 |
| 331 | 特発性多中心性キャッスルマン病 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00231140 (ClinicalTrials.gov) | December 2005 | 30/9/2005 | Pilot-Study of Thalidomide in Amyotrophic Lateral Sclerosis (ALS) | Randomized, Open, Parallel Group Study for the Evaluation of an Oral Dose of 100 mg Thalidomide and Subsequent Dose Escalation of 400 mg Thalidomide in Combination With Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis (ALS) | Drug: Thalidomide (drug) | Charite University, Berlin, Germany | NULL | Terminated | 25 Years | 80 Years | Both | 40 | Phase 2 | Germany |
| 2 | NCT00140452 (ClinicalTrials.gov) | February 2005 | 31/8/2005 | Phase II Study Using Thalidomide for the Treatment of ALS | Phase II Study Using Thalidomide for the Treatment of Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis;ALS | Drug: Thalidomide | Dartmouth-Hitchcock Medical Center | Celgene Corporation | Completed | 18 Years | 80 Years | Both | 24 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000018660 | 2015/08/17 | 17/08/2015 | Japanese POEMS syndrome with thalidmaide trial for compassionate use | Japanese POEMS syndrome with thalidmaide trial for compassionate use - Japanese POEMS syndrome with thalidmaide trial for compassionate use (JPOST15) | Crow-Fukase(POEMS) syndrome | FPF300 (thalidomide)100-300mg/day,at bedtime +Dexamethasone 20mg/day (day1-4) Duration:until the approval of thalidomide for POEMT syndrome | Chiba University Graduate School of Medicine | NULL | Recruiting | 20years-old | Not applicable | Male and Female | 20 | Not selected | Japan |
| 2 | JPRN-JMA-IIA00084 | 22/03/2012 | 19/03/2012 | Japanese POEMS Syndrome with Thalidomide Trial | Japanese POEMS Syndrome with Thalidomide Trial | Crow-Fukase (POEMS) syndrome | Intervention type:DRUG. Intervention1:FPF 300 (thalidomide), Dose form:CAPSULE, Route of administration:ORAL. | J-POST Clinical Trial Office | Hokkaido University, Hokkaido Medical Center, Tohoku University, Chiba University, Saitama Medical University, Niigata University, Shinshu University, Nagoya University, Kinki University, Kobe City Medical Center General Hospital, Yamaguchi University, Kyushu University, Kagoshima University | Completed | >=20 YEARS | No Limit | BOTH | 24 | Phase 3 | Japan |
| 3 | JPRN-JMA-IIA00046 | 13/09/2010 | 06/09/2010 | Japanese POEMS Syndrome with Thalidomide Trial | Thalidomide Treatment for Crow-Fukase (POEMS) Syndrome: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Extension Phase to Evaluate the Long-term Safety | Crow-Fukase (POEMS)syndrome | Intervention type:DRUG. Intervention1:FPF 300 (thalidomide), Dose form:CAPSULE, Route of administration:ORAL. Control intervention1:FPF300 (placebo), Dose form:CAPSULE, Route of administration:ORAL. | J-POST Clinical Trial Office | Hokkaido University, Hokkaido Medical Center, Tohoku University, Chiba University, Saitama Medical University, Niigata University, Shinshu University, Nagoya University, Kinki University, Kobe City Medical Center General Hospital, Yamaguchi University, Kyushu University, Kagoshima University | Completed | >=20 YEARS | No Limit | BOTH | 24 | Japan |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00004450 (ClinicalTrials.gov) | August 1998 | 18/10/1999 | Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy | Adrenoleukodystrophy | Drug: glyceryl trierucate;Drug: glyceryl trioleate;Drug: interferon beta;Drug: thalidomide | FDA Office of Orphan Products Development | Hugo W. Moser Research Institute at Kennedy Krieger, Inc. | Completed | 4 Years | N/A | Male | 60 | N/A | NULL |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04612582 (ClinicalTrials.gov) | January 1, 2020 | 15/6/2020 | Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis | A Comparative Study of Bortezomib-Thalidomide-Dexamethason and Bortezomib-Cyclophosphamide-Dexamethason in the Treatment of Monoclonal Immunoglobulin Light Chain Amyloidosis: A Prospective Randomized Controlled Trial(BTD-CHINA-TRIAL) | Immunoglobulin Light-Chain Amyloidosis | Drug: Thalidomide;Drug: Cyclophosphamide | Guangdong Provincial People's Hospital | NULL | Recruiting | 18 Years | 80 Years | All | 70 | Phase 4 | China |
| 2 | ChiCTR-IPR-17012637 | 2017-10-01 | 2017-09-11 | Prospective Randomized controlled study of the combination regimen of bortezomib + thalidomide + dexamethasone (VTD) and bortezomib + cyclophosphamide + dexamethasone (VCD) for the initial treatment of type AL amyloidosis | Prospective Randomized controlled study of the combination regimen of bortezomib + thalidomide + dexamethasone (VTD) and bortezomib + cyclophosphamide + dexamethasone (VCD) for the initial treatment of type AL amyloidosis | type AL amyloidosis | Group 1:the combination regimen of bortezomib +thalidomide + dexamethasone (VTD);Group 2:the combination regimen of bortezomib + cyclophosphamide + dexamethasone (VCD); | Guangdong General Hospital | NULL | Pending | 18 | 75 | Both | Group 1:35;Group 2:35; | China | |
| 3 | ChiCTR-IPR-16008422 | 2016-05-05 | 2016-05-08 | Randomized controlled study of the combination regimen of bortezomib + cyclophosphamide + dexamethasone (BCD) and bortezomib +thalidomide + dexamethasone (BTD) for the initial treatment of primary systemic amyloidosis (AL) | Randomized controlled study of the combination regimen of bortezomib + cyclophosphamide + dexamethasone (BCD) and bortezomib +thalidomide + dexamethasone (BTD) for the initial treatment of primary systemic amyloidosis (AL) | primary systemic amyloidosis (AL) | the first group: the combination regimen of bortezomib + cyclophosphamide + dexamethasone (BCD);the second group:the combination regimen of bortezomib +thalidomide + dexamethasone (BTD) ; | People's Hospital, Beijing University | NULL | Recruiting | 18 | 75 | Both | the first group:60;the second group:60; | China | |
| 4 | NCT02545907 (ClinicalTrials.gov) | October 2015 | 27/8/2015 | A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis | A Single Arm Open Labeled Multicentre Phase 1b Dose Escalation Study of Carfilzomib Taken in Combination With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis | Amyloidosis | Drug: Carfilzomib;Drug: Thalidomide;Drug: Dexamethasone | University College, London | NULL | Not yet recruiting | 18 Years | N/A | Both | 36 | Phase 1;Phase 2 | United Kingdom |
| 5 | NCT01849783 (ClinicalTrials.gov) | April 4, 2013 | 6/5/2013 | Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma | Single Autologous Transplant Followed by Consolidation and Maintenance for Participants = 65 Years of Age Diagnosed With Multiple Myeloma or a Related Plasma Cell Malignancy | Extramedullary Plasmacytoma;Isolated Plasmacytoma of Bone;Light Chain Deposition Disease;Primary Systemic Amyloidosis;Stage I Multiple Myeloma;Stage II Multiple Myeloma;Stage III Multiple Myeloma | Drug: dexamethasone;Drug: cisplatin;Drug: doxorubicin;Drug: cyclophosphamide;Drug: etoposide;Drug: bortezomib;Drug: thalidomide;Drug: melphalan;Procedure: autologous stem cell transplant | Yogesh Jethava | National Cancer Institute (NCI) | Active, not recruiting | 65 Years | 85 Years | All | 41 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT00064337 (ClinicalTrials.gov) | January 2004 | 8/7/2003 | S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis | S0115, A Phase II Trial Evaluating Modified High Dose Melphalan (100 mg/m) And Autologous Peripheral Blood Stem Cell Supported Transplant (SCT) For High Risk Patients With Multiple Myeloma And/Or Light Chain Amyloidosis (AL Amyloidosis) (A BMT Study) | Multiple Myeloma;Plasma Cell Myeloma | Biological: filgrastim;Drug: cyclophosphamide;Drug: dexamethasone;Drug: melphalan;Drug: thalidomide;Procedure: peripheral blood stem cell transplantation | Southwest Oncology Group | National Cancer Institute (NCI) | Completed | 18 Years | 120 Years | All | 104 | Phase 2 | United States |
| 7 | NCT01527032 (ClinicalTrials.gov) | September 2002 | 28/7/2011 | Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis | Risk-adapted Therapy for AL Amyloidosis | Amyloidosis | Drug: melphalan, thalidomide and dexamethasone | FDA Office of Orphan Products Development | NULL | Completed | Phase 2 | NULL | ||||
| 8 | NCT00089167 (ClinicalTrials.gov) | May 2002 | 4/8/2004 | Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis | Risk Adapted Intravenous Melphalan and Adjuvant Thalidomide and Dexamethasone for Untreated Patients With Primary Systemic Amyloidosis | Multiple Myeloma and Plasma Cell Neoplasm | Biological: filgrastim;Drug: dexamethasone;Drug: melphalan;Drug: thalidomide | Memorial Sloan Kettering Cancer Center. | National Cancer Institute (NCI) | Completed | 18 Years | N/A | Both | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03122431 (ClinicalTrials.gov) | June 5, 2017 | 17/4/2017 | Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases | Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects | Systemic Lupus Erythematosus (SLE);Juvenile SLE;Cutaneous Lupus | Drug: Thalidomide;Drug: Hydroxychloroquine reduced;Drug: Hydroxychloroquine high | University of Sao Paulo General Hospital | Fundação de Amparo à Pesquisa do Estado de São Paulo | Recruiting | 5 Years | 64 Years | All | 296 | Phase 4 | Brazil |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00418132 (ClinicalTrials.gov) | August 2000 | 3/1/2007 | Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis | T Cell Immunity in Collagen Biosynthesis of Scleroderma | Scleroderma, Systemic | Drug: Thalidomide;Drug: Placebo thalidomide | New York University School of Medicine | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Terminated | 18 Years | 65 Years | Both | 30 | Phase 1 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00001599 (ClinicalTrials.gov) | May 1997 | 3/11/1999 | Pilot Study of Thalidomide to Treat Sjogren's Syndrome | Pilot Study of Thalidomide for Sjogren's Syndrome | Sjogren's Syndrome;Xerostomia | Drug: Thalidomide | National Institute of Dental and Craniofacial Research (NIDCR) | NULL | Completed | N/A | N/A | Female | 28 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000037172 | 2021-01-01 | 2020-08-27 | Randomized Double-blind Controlled Study of Shenshi Shengdiqinlian Tufuling Decoction in the Treatment of Mucocutaneous Behcet's Disease | Randomized Double-blind Controlled Study of Shenshi Shengdiqinlian Tufuling Decoction in the Treatment of Mucocutaneous Behcet's Disease | Behcet's Disease | experimental group:Shen's Qinlian Soil Fuling Granules + Thalidomide Tablets;control group:placebo + Thalidomide Tablets ; | Shanghai Traditional Chinese Medicine Hospital | NULL | Pending | 16 | 70 | Both | experimental group:60;control group:60; | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCT2031200236 | 28/09/2017 | 10/12/2020 | Double-blind placebo-controlled clinical trial of thalidomide for chronic granulomatous disease-associated colitis | Double-blind placebo-controlled clinical trial of thalidomide for chronic granulomatous disease-associated colitis | chronic granulomatous disease-associated colitis primary immunodeficiency diseases; inflammatory bowel disease;D006105 | 1) Oral administration of thalidomide (1.5-3mg/kg), once a day 2) Oral administration of placebo (1.5-3mg/kg), once a day | Kawai Toshinao | Kawai Toshinao;Japan Agency for Medical Research and Development | Recruiting | >= 1age old | Not applicable | Both | 8 | Japan | |
| 2 | JPRN-UMIN000029324 | 2017/09/28 | 01/10/2017 | Double-blind placebo-controlled clinical trial of thalidomide for chronic granulomatous disease-associated colitis | Double-blind placebo-controlled clinical trial of thalidomide for chronic granulomatous disease-associated colitis - Clinical trial of thalidomide for CGD colitis | Chronic granulomatous disease associated colitis | Oral administration of thalidomide (1.5-3mg/kg), once a day Oral administration of placebo (1.5-3mg/kg), once a day | National Center for Child Heath and Development | NULL | Recruiting | 1years-old | Not applicable | Male and Female | 8 | Not selected | Japan |
| 3 | JPRN-UMIN000009370 | 2012/12/07 | 21/11/2012 | Thalidomide therapy clinical trial for chronic granulomatous disease-associated intractable granulomatous lesion | Chronic granulomatous disease | Oral administration of thalidomide | National Center for Child Heath and Development | NULL | Complete: follow-up complete | 3years-old | Not applicable | Male and Female | 5 | Not selected | Japan |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00305552 (ClinicalTrials.gov) | February 2005 | 21/3/2006 | SARCOTHAL. Thalidomide in Skin Sarcoidosis | Randomized Controlled Trial of Thalidomide vs Placebo in Skin Sarcoidosis | Sarcoidosis | Drug: THALIDOMIDE | Assistance Publique - Hôpitaux de Paris | NULL | Completed | 18 Years | N/A | Both | 40 | Phase 3 | France |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2010-023828-24-GB (EUCTR) | 09/06/2011 | 27/04/2011 | The effect of Thalidomide on sputum biomarkers in IPF cough. - The effect of Thalidomide on sputum biomarkers in IPF cough | The effect of Thalidomide on sputum biomarkers in IPF cough. - The effect of Thalidomide on sputum biomarkers in IPF cough | Cough in Idiopathic Pulmonary fibrosis. | Trade Name: Thalidomide Pharmion Product Name: Thalidomide Pharmion Trade Name: PREDNISOLONE Product Name: prednisolone | University of Nottingham | NULL | Not Recruiting | Female: yes Male: yes | United Kingdom | ||||
| 2 | NCT00600028 (ClinicalTrials.gov) | December 2007 | 11/1/2008 | Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide | Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide | Idiopathic Pulmonary Fibrosis;Cough | Drug: Thalidomide;Drug: Placebo | Johns Hopkins University | NULL | Completed | 50 Years | N/A | All | 25 | Phase 3 | United States |
| 3 | NCT00162760 (ClinicalTrials.gov) | October 2003 | 8/9/2005 | Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide | Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide | Idiopathic Pulmonary Fibrosis (IPF) | Drug: Thalidomide | Johns Hopkins University | Celgene Corporation | Completed | 50 Years | 80 Years | Both | 19 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00953615 (ClinicalTrials.gov) | April 2006 | 4/8/2009 | Thalidomide for the Treatment of Primary Sclerosing Cholangitis (PSC) | Open Label, Phase II Investigation of Thalidomide for the Treatment of Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | Drug: Thalidomide | Mayo Clinic | Celgene Corporation | Terminated | 18 Years | 72 Years | All | 1 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03221166 (ClinicalTrials.gov) | February 27, 2018 | 5/7/2017 | Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors | Thalidomide, a Novel Immunological Treatment to Modify the Natural History of Paediatric Crohn's Disease: a New Proposal From a Well-established Paediatric Research Network | Crohn Disease | Drug: Thalidomide;Drug: Infliximab | IRCCS Burlo Garofolo | Centro di Riferimento Oncologico - Aviano;Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | Terminated | 6 Years | 17 Years | All | 9 | Phase 3 | Italy |
| 2 | EUCTR2016-000786-24-IT (EUCTR) | 07/03/2017 | 30/11/2016 | Efficacy and safety of thalidomide in pediatric patients with Crohn's disease | Thalidomide, a novel immunological treatment to modify the natural history of paediatric Crohn's disease: a new proposal from a well-established paediatric research network - Talidomide in Crohn disease in Pediatrics | Crohn's Disease MedDRA version: 19.0;Level: LLT;Classification code 10011402;Term: Crohn's disease (colon);System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | IRCCS Burlo Garofolo | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 124 | Phase 3 | Italy | |||
| 3 | NCT02998827 (ClinicalTrials.gov) | November 2016 | 24/11/2016 | Thalidomide Results in Diminished Ovarian Reserve in Reproductive Age Female IBD Patients | Crohn Disease | Drug: Thalidomide;Drug: infliximab, azathioprine;Other: enteral nutrition | Sixth Affiliated Hospital, Sun Yat-sen University | NULL | Enrolling by invitation | N/A | N/A | Female | 90 | N/A | NULL | |
| 4 | NCT02956538 (ClinicalTrials.gov) | October 2016 | 13/10/2016 | Induced Adult Refractory Active Crohn's Disease Clinical Relieving by Using Thalidomide | Induced Adult Refractory Active Crohn's Disease Clinical Relieving by Using Thalidomide: A Randomized, Double-blind, Placebo-controlled Multicenter Clinical Study | Crohn Disease | Drug: Thalidomide;Drug: placebo(for thalidomide) | Sixth Affiliated Hospital, Sun Yat-sen University | NULL | Recruiting | 18 Years | 50 Years | Both | 72 | Phase 0 | China |
| 5 | ChiCTR-OPC-16008655 | 2016-05-01 | 2016-06-16 | Efficacy and safety of thalidomide for patients with Crohn's Disease: a prospective multicenter observational study from China | Efficacy and safety of thalidomide for patients with Crohn's Disease: a prospective multicenter observational study from China | Crohn‘s Disease | 1:Thalidomide 75-100mg qd;2:Thalidomide 150-200mg qd;3:Thalidomide 75-100mg qd+MTX 20-25mg /W; | Peking Union Medical College Hospital | NULL | Recruiting | 16 | 70 | Both | 1:90;2:90;3:90; | China | |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT02501291 (ClinicalTrials.gov) | January 2013 | 20/5/2015 | Thalidomide in Treating Crohn's Disease | Thalidomide in Inducing and Maintaining Remission of Crohn's Disease | Crohn's Disease | Drug: Thalidomide | First Affiliated Hospital, Sun Yat-Sen University | NULL | Completed | 18 Years | 75 Years | Both | 47 | Phase 2 | China |
| 7 | NCT00720538 (ClinicalTrials.gov) | August 2008 | 18/7/2008 | Thalidomide in Pediatric Inflammatory Bowel Diseases. | Randomized Controlled Double-blind Vs. Placebo Multicentre Study on the Safety and Effectiveness of Thalidomide in the Treatment of Refractory Crohn's Disease and Ulcerative Colitis. | Inflammatory Bowel Diseases;Crohn's Disease;Ulcerative Colitis | Drug: Thalidomide;Drug: placebo | IRCCS Burlo Garofolo | Ospedale Meyer;Pediatric Gastroenterology Unit, IRCCS Gaslini, Genoa.;Vittore Buzzi Children's Hospital;University of Pisa;Pediatric Gastroenterology Unit, University of Messina.;Università degli Studi di Brescia;University of Trieste | Completed | 2 Years | 18 Years | Both | 84 | Phase 3 | Italy |
| 8 | EUCTR2005-005414-20-IT (EUCTR) | 06/03/2006 | 31/01/2006 | Randomized controlled double-blind Vs. placebo multicentre study on the safety and effectiveness of thalidomide in the treatment of refractory Crohn s disease and ulcerative colitis. - Thalidomide and IBD | Randomized controlled double-blind Vs. placebo multicentre study on the safety and effectiveness of thalidomide in the treatment of refractory Crohn s disease and ulcerative colitis. - Thalidomide and IBD | Inflammatory Bowel Disease Crohn Disease, Ulcerative Colitis MedDRA version: 6.1;Level: PT;Classification code 10021972 | Trade Name: Thalidomide Pharmion INN or Proposed INN: Thalidomide | ISTITUTO PER L INFANZIA BURLO GAROFOLO | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 124 | Italy |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00720538 (ClinicalTrials.gov) | August 2008 | 18/7/2008 | Thalidomide in Pediatric Inflammatory Bowel Diseases. | Randomized Controlled Double-blind Vs. Placebo Multicentre Study on the Safety and Effectiveness of Thalidomide in the Treatment of Refractory Crohn's Disease and Ulcerative Colitis. | Inflammatory Bowel Diseases;Crohn's Disease;Ulcerative Colitis | Drug: Thalidomide;Drug: placebo | IRCCS Burlo Garofolo | Ospedale Meyer;Pediatric Gastroenterology Unit, IRCCS Gaslini, Genoa.;Vittore Buzzi Children's Hospital;University of Pisa;Pediatric Gastroenterology Unit, University of Messina.;Università degli Studi di Brescia;University of Trieste | Completed | 2 Years | 18 Years | Both | 84 | Phase 3 | Italy |
| 2 | EUCTR2005-005414-20-IT (EUCTR) | 06/03/2006 | 31/01/2006 | Randomized controlled double-blind Vs. placebo multicentre study on the safety and effectiveness of thalidomide in the treatment of refractory Crohn s disease and ulcerative colitis. - Thalidomide and IBD | Randomized controlled double-blind Vs. placebo multicentre study on the safety and effectiveness of thalidomide in the treatment of refractory Crohn s disease and ulcerative colitis. - Thalidomide and IBD | Inflammatory Bowel Disease Crohn Disease, Ulcerative Colitis MedDRA version: 6.1;Level: PT;Classification code 10021972 | Trade Name: Thalidomide Pharmion INN or Proposed INN: Thalidomide | ISTITUTO PER L INFANZIA BURLO GAROFOLO | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 124 | Italy |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01485224 (ClinicalTrials.gov) | November 2011 | 28/11/2011 | Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia | Efficacy of Thalidomide in the Treatment of Severe Recurrent Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) | Hereditary Hemorrhagic Telangiectasia;Epistaxis | Drug: Thalidomide | IRCCS Policlinico S. Matteo | NULL | Completed | 18 Years | N/A | All | 31 | Phase 2 | Italy |
| 2 | EUCTR2011-004096-36-IT (EUCTR) | 11/10/2011 | 19/03/2012 | Efficacy of thalidomide in the treatment of heavy and frequent nose bleeding in patients affected by hereditary hemorrhagic telangiectasia | Efficacy of thalidomide in the treatment of severe recurrent epistaxis in hereditary hemorrhagic telangiectasia (HHT) | Severe recurrent epistaxis in hereditary hemorrhagic telangiectasia MedDRA version: 14.1;Level: LLT;Classification code 10038554;Term: Rendu-Osler-Weber syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Trade Name: THALIDOMIDE CELGENE*28CPS 50MG INN or Proposed INN: THALIDOMIDE | OSPEDALE POLICLINICO S. MATTEO | NULL | Not Recruiting | Female: yes Male: yes | 31 | Phase 2 | Italy | ||
| 3 | NCT00389935 (ClinicalTrials.gov) | October 2006 | 17/10/2006 | Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding | Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding | Arteriovenous Malformation;Hereditary Hemorrhagic Telangiectasia;Hematochezia;Melena | Drug: Thalidomide | Northport Veterans Affairs Medical Center | Georgia Regents University;University of Massachusetts, Worcester | Completed | 18 Years | N/A | Both | 14 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR-TRC-13003449 | 2013-04-25 | 2013-06-07 | A multicenter, randomized, double-blind, placebo-controlled, Phase II clinical study of Thalidomide in the treatment of Ankylosing Spondylitis | A multicenter, randomized, double-blind, placebo-controlled, Phase II clinical study of Thalidomide in the treatment of Ankylosing Spondylitis | Ankylosing Spondylitis | Thalidomide 150mg:Thalidomide 25mg/qd.po.2weeks; 50mg/qd.po.2weeks;100mg/qd.po.2weeks; 150mg/qd, po., to the end;Thalidomide 100mg:Thalidomide 25mg/qd.po.2weeks; 50mg/qd.po.2weeks; 100mg/qd.po.to the end;Control group:Placebo po.; | The General Hospital of People's Liberation Army | NULL | Completed | 18 | 65 | Both | Thalidomide 150mg:80;Thalidomide 100mg:80;Control group:40; | 2 (Phase 2 study) | China |
| 2 | NCT02201043 (ClinicalTrials.gov) | February 2013 | 23/7/2014 | Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing Spondylitis | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing Spondylitis | Ankylosing Spondylitis | Drug: Thalidomide 150mg;Drug: Thalidomide 100mg;Drug: Placebo | Shanghai Pharmaceuticals Holding Co., Ltd | NULL | Completed | 18 Years | 65 Years | Both | 197 | Phase 2 | China |
| 3 | ChiCTR-ONRC-10000858 | 2010-05-10 | 2010-04-28 | Research on safety tolerance and pharmacokinetics of oral muti-dose Thalidomide | Research on safety tolerance and pharmacokinetics of oral muti-dose Thalidomide | Ankylosing Spondylitis | Group A:Muti-dose Thalidomide;GroupB:Muti-dose Thalidomide and Diclofenac sodium enteric-coated tablets ; | Chinese PLA General Hospital | NULL | Completed | 18 | 45 | Both | Group A:15;GroupB:12; | I (Phase 1 study) | China |
| 4 | ChiCTR-ONRC-11001846 | 2009-12-03 | 2011-12-28 | The research of immue state and current treatment in Ankylosing spondylitis | The research of immue state and current treatment in Ankylosing spondylitis | Ankylosing spondylitis | Traditional therapy group:DMARDs;biological agent group:biological agent;thalidomide group:thalidomide; | Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University | NULL | Completed | 18 | 65 | Both | Traditional therapy group:500;biological agent group:500;thalidomide group:500; | NULL |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR1900021901 | 2019-03-20 | 2019-03-15 | Efficacy and Safety of Thalidomide for the Treatment of Arteriovenous Malformations in Central Nervous System: Pilot Study | Efficacy and Safety of Thalidomide for the Treatment of Arteriovenous Malformations in Central Nervous System: Pilot Study | central nervous system arteriovenous malformations | Case series:Oral thalidomide; | Xuanwu Hospital, Capital Medical University | NULL | Completed | Both | Case series:30; | China | |||
| 2 | NCT00389935 (ClinicalTrials.gov) | October 2006 | 17/10/2006 | Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding | Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding | Arteriovenous Malformation;Hereditary Hemorrhagic Telangiectasia;Hematochezia;Melena | Drug: Thalidomide | Northport Veterans Affairs Medical Center | Georgia Regents University;University of Massachusetts, Worcester | Completed | 18 Years | N/A | Both | 14 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00469703 (ClinicalTrials.gov) | August 2005 | 3/5/2007 | Safety and Efficacy Study of Thalomid in Patients With Chronic Pancreatitis | A Phase II, Open-Label, Single Center Pilot Study to Determine the Safety and Efficacy of THALOMID (Thalidomide) in Patients With Chronic Pancreatitis. | Chronic Pancreatitis | Drug: Thalidomide | Winthrop University Hospital | Celgene Corporation | Terminated | 18 Years | 75 Years | Both | 10 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000028918 | 2020-01-01 | 2020-01-07 | A randomized, double-blind controlled study of glucocorticoids combination with thalidomide in the treatment of IgG4-related diseases | Efficacy and safety of thalidomide in IgG4-related diseases | IgG4 related disease | control group:prednison combined with placebo;experimental group:prednison combined with thalidomide; | Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | NULL | Recruiting | 18 | 80 | Both | control group:51;experimental group:51; | Phase 4 | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03043105 (ClinicalTrials.gov) | January 1, 2017 | 31/1/2017 | TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial | Thalidomide, Cyclophosphamide and Prednisone in Newly Diagnosed Multicentric Castleman's Disease: a Prospective, Single-center, Single-arm, Phase-II Pilot Trial | Multicentric Castleman Disease | Drug: Thalidomide, cyclophosphamide and prednisone | Peking Union Medical College Hospital | NULL | Active, not recruiting | 18 Years | N/A | All | 25 | Phase 2 | China |